AU2015274334B2 - Compositions and methods for treating cancers - Google Patents

Compositions and methods for treating cancers Download PDF

Info

Publication number
AU2015274334B2
AU2015274334B2 AU2015274334A AU2015274334A AU2015274334B2 AU 2015274334 B2 AU2015274334 B2 AU 2015274334B2 AU 2015274334 A AU2015274334 A AU 2015274334A AU 2015274334 A AU2015274334 A AU 2015274334A AU 2015274334 B2 AU2015274334 B2 AU 2015274334B2
Authority
AU
Australia
Prior art keywords
inhibitor
compound
alkyl
substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015274334A
Other languages
English (en)
Other versions
AU2015274334A1 (en
Inventor
Mouad Edderkaoui
Ramachandran Murali
Stephen Pandol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2015274334A1 publication Critical patent/AU2015274334A1/en
Application granted granted Critical
Publication of AU2015274334B2 publication Critical patent/AU2015274334B2/en
Priority to AU2021201667A priority Critical patent/AU2021201667B2/en
Priority to AU2023200895A priority patent/AU2023200895A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015274334A 2014-06-12 2015-06-12 Compositions and methods for treating cancers Active AU2015274334B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021201667A AU2021201667B2 (en) 2014-06-12 2021-03-17 Compositions and methods for treating cancers
AU2023200895A AU2023200895A1 (en) 2014-06-12 2023-02-16 Compositions and methods for treating cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011413P 2014-06-12 2014-06-12
US62/011,413 2014-06-12
PCT/US2015/035659 WO2015192078A1 (en) 2014-06-12 2015-06-12 Compositions and methods for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201667A Division AU2021201667B2 (en) 2014-06-12 2021-03-17 Compositions and methods for treating cancers

Publications (2)

Publication Number Publication Date
AU2015274334A1 AU2015274334A1 (en) 2016-12-15
AU2015274334B2 true AU2015274334B2 (en) 2020-12-17

Family

ID=54834452

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015274334A Active AU2015274334B2 (en) 2014-06-12 2015-06-12 Compositions and methods for treating cancers
AU2021201667A Active AU2021201667B2 (en) 2014-06-12 2021-03-17 Compositions and methods for treating cancers
AU2023200895A Abandoned AU2023200895A1 (en) 2014-06-12 2023-02-16 Compositions and methods for treating cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021201667A Active AU2021201667B2 (en) 2014-06-12 2021-03-17 Compositions and methods for treating cancers
AU2023200895A Abandoned AU2023200895A1 (en) 2014-06-12 2023-02-16 Compositions and methods for treating cancers

Country Status (10)

Country Link
US (4) US10029997B2 (enExample)
EP (2) EP4306173A3 (enExample)
JP (2) JP6663863B2 (enExample)
KR (1) KR102567244B1 (enExample)
CN (1) CN106794175B (enExample)
AU (3) AU2015274334B2 (enExample)
CA (1) CA2950774C (enExample)
ES (1) ES2960601T3 (enExample)
MX (1) MX388409B (enExample)
WO (1) WO2015192078A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960601T3 (es) 2014-06-12 2024-03-05 Cedars Sinai Medical Center Composiciones y métodos para el tratamiento del cáncer
IT201700041723A1 (it) * 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
US20230293457A1 (en) * 2020-02-26 2023-09-21 Shanghaitech University Application of disulfiram in coronavirus resistance
CN111658766A (zh) * 2020-07-06 2020-09-15 陈长宏 GSK3β及其激动剂在上皮源性恶性肿瘤治疗与康复中的应用
WO2024019667A1 (en) * 2022-07-21 2024-01-25 Agency For Science, Technology And Research Method of inhibiting epithelial-mesenchymal transition and cancer metastasis
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059874A1 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
US20050038113A1 (en) * 2001-09-18 2005-02-17 G2M Cancer Drugs Ag Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
US20090081318A1 (en) * 2005-12-23 2009-03-26 Gelbard Harris A Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711492A (en) * 1970-12-08 1973-01-16 Basf Ag Thiadiazolidinediones
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6333324B1 (en) * 1996-12-17 2001-12-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of MMP or TNF
US6045925A (en) 1997-08-05 2000-04-04 Kansas State University Research Foundation Encapsulated nanometer magnetic particles
YU85403A (sh) * 2001-05-11 2006-03-03 Pharmacia Corporation Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
US6676729B2 (en) 2002-01-02 2004-01-13 International Business Machines Corporation Metal salt reduction to form alloy nanoparticles
EP1339075A1 (en) 2002-02-25 2003-08-27 Motorola, Inc. Magnetic nanomaterials and synthesis method
US6878445B2 (en) 2002-03-08 2005-04-12 Fuji Photo Film Co., Ltd. Nanoparticle coated material and production method of same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
EP1622615A4 (en) * 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
TW593158B (en) 2003-07-31 2004-06-21 Ind Tech Res Inst Magnetic nanoparticle
US7396589B2 (en) 2003-07-31 2008-07-08 Industrial Technology Research Institute Core-shell magnetic nanoparticles comprising an inner-transition element
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US7700193B2 (en) 2005-04-08 2010-04-20 Industrial Technology Research Institute Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof
US20070264199A1 (en) 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
WO2008154642A2 (en) * 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
WO2012012320A1 (en) * 2010-07-19 2012-01-26 Millenium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2013008162A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
DE102011106990B3 (de) 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
NZ630615A (en) * 2012-02-24 2015-09-25 Asd Therapeutics Partners Llc Thiadiazolidinediones as gsk-3 inhibitors
JP5722264B2 (ja) 2012-03-23 2015-05-20 株式会社日立ハイテクノロジーズ データ処理装置、データ容量増加抑制方法
MX364295B (es) 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
CN103848795B (zh) 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
ES2960601T3 (es) 2014-06-12 2024-03-05 Cedars Sinai Medical Center Composiciones y métodos para el tratamiento del cáncer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059874A1 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
US20050038113A1 (en) * 2001-09-18 2005-02-17 G2M Cancer Drugs Ag Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
US20090081318A1 (en) * 2005-12-23 2009-03-26 Gelbard Harris A Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3

Also Published As

Publication number Publication date
US20170121297A1 (en) 2017-05-04
CN106794175B (zh) 2020-06-09
MX388409B (es) 2025-03-19
CA2950774A1 (en) 2015-12-17
EP3154544A4 (en) 2017-12-20
EP4306173A3 (en) 2024-04-10
AU2021201667B2 (en) 2022-11-17
US10836735B2 (en) 2020-11-17
US20180297965A1 (en) 2018-10-18
AU2015274334A1 (en) 2016-12-15
US20190194152A1 (en) 2019-06-27
US20210276964A1 (en) 2021-09-09
EP3154544A1 (en) 2017-04-19
MX2016016507A (es) 2017-04-27
AU2023200895A1 (en) 2023-03-16
JP6663863B2 (ja) 2020-03-13
CN106794175A (zh) 2017-05-31
JP2020090537A (ja) 2020-06-11
US10266505B2 (en) 2019-04-23
KR20170015507A (ko) 2017-02-08
EP3154544B1 (en) 2023-08-02
JP2017523141A (ja) 2017-08-17
AU2021201667A1 (en) 2021-04-08
US10029997B2 (en) 2018-07-24
JP7015856B2 (ja) 2022-02-03
CA2950774C (en) 2023-03-21
EP4306173A2 (en) 2024-01-17
KR102567244B1 (ko) 2023-08-16
WO2015192078A1 (en) 2015-12-17
ES2960601T3 (es) 2024-03-05

Similar Documents

Publication Publication Date Title
AU2021201667B2 (en) Compositions and methods for treating cancers
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
JP2025069232A (ja) 薬物送達のためのイオン液体
US11248016B2 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
KR20250053841A (ko) 암의 치료 및/또는 예방을 위한 의약품
HK1238131B (zh) 用於治疗癌症的组合物
HK1238131A1 (en) Compositions for treating cancers
EP4611749A2 (en) Compounds and methods for treating cancers
CN111018739A (zh) 一种氨甲环酸衍生物及其制备方法和在制备治疗口腔癌药物中的用途
Steele The clinical pharmacology of methotrexate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)